BMEA Key Statistics, Chart & Performance
The current stock price of BMEA is 1.32 USD. In the past month the price increased by 23.36%. In the past year, price decreased by -67%.
BMEA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 42 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Company Info
BIOMEA FUSION INC
1599 Industrial Road
San Carlos CALIFORNIA US
Employees: 42
Phone: 16509809099
BIOMEA FUSION INC / BMEA FAQ
What does BMEA do?
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 42 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
What is the current price of BMEA stock?
The current stock price of BMEA is 1.32 USD. The price increased by 2.33% in the last trading session.
Does BIOMEA FUSION INC pay dividends?
BMEA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BMEA stock?
BMEA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BMEA stock to perform?
13 analysts have analysed BMEA and the average price target is 7.14 USD. This implies a price increase of 440.91% is expected in the next year compared to the current price of 1.32.
What is the ownership structure of BIOMEA FUSION INC (BMEA)?
You can find the ownership structure of BIOMEA FUSION INC (BMEA) on the Ownership tab.
BMEA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BMEA. When comparing the yearly performance of all stocks, BMEA is a bad performer in the overall market: 94.84% of all stocks are doing better.
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. While BMEA seems to be doing ok healthwise, there are quite some concerns on its profitability.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 40.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.43% | ||
| ROE | -612.79% | ||
| Debt/Equity | 0 |
BMEA Forecast & Estimates
13 analysts have analysed BMEA and the average price target is 7.14 USD. This implies a price increase of 440.91% is expected in the next year compared to the current price of 1.32.